206 related articles for article (PubMed ID: 31831875)
1. Next-generation hypomethylating agent SGI-110 primes acute myeloid leukemia cells to IAP antagonist by activating extrinsic and intrinsic apoptosis pathways.
Dittmann J; Haydn T; Metzger P; Ward GA; Boerries M; Vogler M; Fulda S
Cell Death Differ; 2020 Jun; 27(6):1878-1895. PubMed ID: 31831875
[TBL] [Abstract][Full Text] [Related]
2. Dual Antagonist of cIAP/XIAP ASTX660 Sensitizes HPV
Xiao R; An Y; Ye W; Derakhshan A; Cheng H; Yang X; Allen C; Chen Z; Schmitt NC; Van Waes C
Clin Cancer Res; 2019 Nov; 25(21):6463-6474. PubMed ID: 31266830
[TBL] [Abstract][Full Text] [Related]
3. The non-peptidomimetic IAP antagonist ASTX660 sensitizes colorectal cancer cells for extrinsic apoptosis.
Knoll G; Ehrenschwender M
FEBS Open Bio; 2021 Mar; 11(3):714-723. PubMed ID: 33484626
[TBL] [Abstract][Full Text] [Related]
4. Clinical Positioning of the IAP Antagonist Tolinapant (ASTX660) in Colorectal Cancer.
Crawford N; Stott KJ; Sessler T; McCann C; McDaid W; Lees A; Latimer C; Fox JP; Munck JM; Smyth T; Shah A; Martins V; Lawler M; Dunne PD; Kerr EM; McDade SS; Coyle VM; Longley DB
Mol Cancer Ther; 2021 Sep; 20(9):1627-1639. PubMed ID: 34389694
[TBL] [Abstract][Full Text] [Related]
5. Smac mimetic primes apoptosis-resistant acute myeloid leukaemia cells for cytarabine-induced cell death by triggering necroptosis.
Chromik J; Safferthal C; Serve H; Fulda S
Cancer Lett; 2014 Mar; 344(1):101-109. PubMed ID: 24184825
[TBL] [Abstract][Full Text] [Related]
6. ASTX660, an antagonist of cIAP1/2 and XIAP, increases antigen processing machinery and can enhance radiation-induced immunogenic cell death in preclinical models of head and neck cancer.
Ye W; Gunti S; Allen CT; Hong Y; Clavijo PE; Van Waes C; Schmitt NC
Oncoimmunology; 2020; 9(1):1710398. PubMed ID: 32002309
[TBL] [Abstract][Full Text] [Related]
7. ASTX660, a Novel Non-peptidomimetic Antagonist of cIAP1/2 and XIAP, Potently Induces TNFα-Dependent Apoptosis in Cancer Cell Lines and Inhibits Tumor Growth.
Ward GA; Lewis EJ; Ahn JS; Johnson CN; Lyons JF; Martins V; Munck JM; Rich SJ; Smyth T; Thompson NT; Williams PA; Wilsher NE; Wallis NG; Chessari G
Mol Cancer Ther; 2018 Jul; 17(7):1381-1391. PubMed ID: 29695633
[TBL] [Abstract][Full Text] [Related]
8. Smac mimetic and demethylating agents synergistically trigger cell death in acute myeloid leukemia cells and overcome apoptosis resistance by inducing necroptosis.
Steinhart L; Belz K; Fulda S
Cell Death Dis; 2013 Sep; 4(9):e802. PubMed ID: 24030154
[TBL] [Abstract][Full Text] [Related]
9. Synergistic targeting of AML stem/progenitor cells with IAP antagonist birinapant and demethylating agents.
Carter BZ; Mak PY; Mak DH; Shi Y; Qiu Y; Bogenberger JM; Mu H; Tibes R; Yao H; Coombes KR; Jacamo RO; McQueen T; Kornblau SM; Andreeff M
J Natl Cancer Inst; 2014 Feb; 106(2):djt440. PubMed ID: 24526787
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic targeting of necroptosis by Smac mimetic bypasses apoptosis resistance in acute myeloid leukemia cells.
Safferthal C; Rohde K; Fulda S
Oncogene; 2017 Mar; 36(11):1487-1502. PubMed ID: 27869161
[TBL] [Abstract][Full Text] [Related]
11. Identification of a novel synergistic induction of cell death by Smac mimetic and HDAC inhibitors in acute myeloid leukemia cells.
Steinwascher S; Nugues AL; Schoeneberger H; Fulda S
Cancer Lett; 2015 Sep; 366(1):32-43. PubMed ID: 26028172
[TBL] [Abstract][Full Text] [Related]
12. RIP1 is required for IAP inhibitor-mediated sensitization for TRAIL-induced apoptosis via a RIP1/FADD/caspase-8 cell death complex.
Abhari BA; Cristofanon S; Kappler R; von Schweinitz D; Humphreys R; Fulda S
Oncogene; 2013 Jul; 32(27):3263-73. PubMed ID: 22890322
[TBL] [Abstract][Full Text] [Related]
13. X-linked inhibitor of apoptosis inhibition sensitizes acute myeloid leukemia cell response to TRAIL and chemotherapy through potentiated induction of proapoptotic machinery.
Zhou J; Lu X; Tan TZ; Chng WJ
Mol Oncol; 2018 Jan; 12(1):33-47. PubMed ID: 29063676
[TBL] [Abstract][Full Text] [Related]
14. Medicarpin, a legume phytoalexin sensitizes myeloid leukemia cells to TRAIL-induced apoptosis through the induction of DR5 and activation of the ROS-JNK-CHOP pathway.
Trivedi R; Maurya R; Mishra DP
Cell Death Dis; 2014 Oct; 5(10):e1465. PubMed ID: 25321472
[TBL] [Abstract][Full Text] [Related]
15. Synergistic interaction of Smac mimetic and IFNα to trigger apoptosis in acute myeloid leukemia cells.
Bake V; Roesler S; Eckhardt I; Belz K; Fulda S
Cancer Lett; 2014 Dec; 355(2):224-31. PubMed ID: 25179908
[TBL] [Abstract][Full Text] [Related]
16. TAS4464, a NEDD8-activating enzyme inhibitor, activates both intrinsic and extrinsic apoptotic pathways via c-Myc-mediated regulation in acute myeloid leukemia.
Ochiiwa H; Ailiken G; Yokoyama M; Yamagata K; Nagano H; Yoshimura C; Muraoka H; Ishida K; Haruma T; Nakayama A; Hashimoto N; Murata K; Nishimura M; Kawashima Y; Ohara O; Ohkubo S; Tanaka T
Oncogene; 2021 Feb; 40(7):1217-1230. PubMed ID: 33420360
[TBL] [Abstract][Full Text] [Related]
17. Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5.
Carter BZ; Mak DH; Schober WD; Dietrich MF; Pinilla C; Vassilev LT; Reed JC; Andreeff M
Blood; 2008 Apr; 111(7):3742-50. PubMed ID: 18187663
[TBL] [Abstract][Full Text] [Related]
18. Survivin inhibitor YM-155 sensitizes tumor necrosis factor- related apoptosis-inducing ligand-resistant glioma cells to apoptosis through Mcl-1 downregulation and by engaging the mitochondrial death pathway.
Premkumar DR; Jane EP; Foster KA; Pollack IF
J Pharmacol Exp Ther; 2013 Aug; 346(2):201-10. PubMed ID: 23740602
[TBL] [Abstract][Full Text] [Related]
19. Guadecitabine (SGI-110): an investigational drug for the treatment of myelodysplastic syndrome and acute myeloid leukemia.
Daher-Reyes GS; Merchan BM; Yee KWL
Expert Opin Investig Drugs; 2019 Oct; 28(10):835-849. PubMed ID: 31510809
[No Abstract] [Full Text] [Related]
20. Cotreatment with Smac mimetics and demethylating agents induces both apoptotic and necroptotic cell death pathways in acute lymphoblastic leukemia cells.
Gerges S; Rohde K; Fulda S
Cancer Lett; 2016 May; 375(1):127-132. PubMed ID: 26944210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
